KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Listed on the Nasdaq, Kiniksa Pharmaceuticals International plc is the UK-based holding company for a biopharmaceutical group focused on developing and commercialising therapies for cardiovascular and inflammatory diseases.
Get an alert when KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£124M
USD 165,596,000
-8.8% vs 2024
Net assets
£425M
USD 567,606,000
+30.9% highest in 3 filed years
Employees
338
+9.4% highest in 3 filed years
Profit before tax
—
Period ending 2025-12-31
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
4-year trend · vs Health Care median
Accounts
4-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|
| Turnover | £91,723,312 | £174,559,066 | £339,955,083 | £511,883,515 | +50.6% | |
| Operating profit | £25,223,087 | -£18,862,105 | -£2,802,066 | £5,413,236 | +293.2% | |
| Profit before tax | £8,254,230 | £12,495,883 | -£27,063,932 | — | — | |
| Net profit | — | — | -£32,334,930 | £44,172,032 | +236.6% | |
| Cash | — | £20,530,768 | £135,934,272 | £123,967,660 | -8.8% | |
| Total assets less current liabilities | — | — | £359,284,324 | £467,471,927 | +30.1% | |
| Net assets | — | £260,777,811 | £324,626,441 | £424,918,401 | +30.9% | |
| Equity | — | £260,777,811 | £324,626,441 | £424,918,401 | +30.9% | |
| Average employees | — | 252 | 309 | 338 | +9.4% | |
| Wages | — | £43,771,639 | £63,761,791 | £74,583,770 | +17% | |
| Directors' remuneration | — | £1,276,005 | £2,427,936 | £2,480,386 | +2.2% |
Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|
| Operating margin | 27.5% | -10.8% | -0.8% | 1.1% | |
| Net margin | — | — | -9.5% | 8.6% | |
| Return on capital employed | — | — | -0.8% | 1.2% | |
| Gearing (liabilities / total assets) | — | — | — | 25.7% | |
| Current ratio | — | 2.33x | 3.29x | 1.51x | |
| Interest cover | 11.08x | -8.25x | -1.19x | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the group's and the company's ability to continue as a going concern.”
Group structure
- KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC · parent
- Kiniksa Pharmaceuticals Corp. 100%
- Primatope Therapeutics, Inc. 100%
- Kiniksa Pharmaceuticals (UK), Ltd. 100%
- Kiniksa Pharmaceuticals (Germany) GmbH 100%
- Kiniksa Pharmaceuticals (France) SARL 100%
- Kiniksa Pharmaceuticals 100%
Significant events
- “Kiniksa International, incorporated on 9 April 2024, is the successor issuer to Kiniksa Pharmaceuticals, Ltd. ('Kiniksa Bermuda'). On 7 June 2024, Kiniksa International and Kiniksa Bermuda completed a transaction pursuant to a Bermuda court-approved scheme of arrangement (the 'Scheme'), which had been previously approved by Kiniksa Bermuda's shareholders.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
11 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BARRY, Douglas, Mr. | Secretary | 2025-09-18 | — | — |
| BAKER, Felix James, Dr | Director | 2024-06-27 | Mar 1969 | American |
| BIGGAR, Stephen Richard | Director | 2024-06-27 | Sep 1970 | American |
| BOYD, Meta Cantey | Director | 2024-10-04 | Dec 1979 | American |
| COLE, Gordon Bradley | Director | 2024-06-27 | Jan 1956 | American |
| LEVY, Richard Steven | Director | 2024-06-27 | May 1957 | American |
| MALLEY, Thomas Robert | Director | 2024-06-27 | Dec 1968 | American |
| MCCAIN, Tracey Lorene | Director | 2024-06-27 | Nov 1967 | American |
| PATEL, Sanjiv | Director | 2024-04-09 | Jul 1969 | American |
| POPOVITS, Kimberly Johnston | Director | 2024-06-27 | Dec 1958 | American |
| QUART, Barry Davd, Dr. | Director | 2024-06-27 | Jan 1957 | American |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ZEYLIKMAN, Madelyn | Secretary | 2024-04-09 | 2025-09-18 |
| MEGNA, Michael | Director | 2024-04-09 | 2024-06-27 |
| MOAT, Ross Michael | Director | 2024-04-09 | 2024-06-27 |
| RAGOSA, Mark | Director | 2024-04-09 | 2024-06-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Baker Bros. Advisors Lp | Corporate entity | Shares 25–50% | 2024-06-28 | Ceased 2025-07-01 |
| Sanjiv Patel | Individual | Voting 25–50% | 2024-06-28 | Active |
| Mr Felix James Baker | Individual | Shares 25–50% | 2024-06-27 | Active |
| Kiniksa Pharmaceuticals, Ltd. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-04-09 | Ceased 2024-06-28 |
Filing timeline
Last 20 of 64 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-26 | SH01 | capital | Capital allotment shares | |
| 2026-06-21 | AA | accounts | Accounts with accounts type group | |
| 2026-05-26 | SH01 | capital | Capital allotment shares | |
| 2026-05-05 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-04-30 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-23 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-23 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-03-13 | SH01 | capital | Capital allotment shares | |
| 2026-02-23 | SH01 | capital | Capital allotment shares | |
| 2026-01-19 | SH01 | capital | Capital allotment shares | |
| 2025-12-16 | SH01 | capital | Capital allotment shares | |
| 2025-12-03 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-12-03 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 20
- Capital events
- 7
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.